{"id":3224,"date":"2026-07-31T08:00:00","date_gmt":"2026-07-31T08:00:00","guid":{"rendered":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/"},"modified":"2026-08-03T10:59:04","modified_gmt":"2026-08-03T10:59:04","slug":"gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons","status":"publish","type":"post","link":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/","title":{"rendered":"Achieve Therapeutics: a first-in-class, disease-modifying remedy for Parkinson&#8217;s"},"content":{"rendered":"<p><br \/>\n<\/p>\n<div id=\"show-notes\" role=\"tabpanel\" aria-labelledby=\"show-notes-tab\" tabindex=\"0\" dir=\"auto\" data-controller=\"convert-links-to-open-in-new-tab\" data-tabs-target=\"panel\" data-tabs-panel=\"show-notes\">\n<p>At the moment we welcome Gene Mack, President and CEO of Achieve Therapeutics.\u00a0<\/p>\n<p>With over 25 years of expertise spanning biochemistry, Wall Road evaluation, and biotech management, Gene brings deep experience in capital markets, technique, and drug growth. He joined Achieve in 2024 and stepped into the CEO function in early 2025.<\/p>\n<p>Achieve Therapeutics is a clinical-stage biotech pioneering next-generation allosteric small molecule therapies. Utilizing its proprietary Magellan platform, which mixes 3D structural biology and physics-based modeling, the corporate is unlocking novel therapies for difficult issues. Their lead candidate is advancing towards Part 2 as a possible first-in-class disease-modifying remedy for Parkinson\u2019s illness, with promising Part 1b information exhibiting biomarker enhancements and useful advantages.<\/p>\n<p>On this episode, we\u2019ll discover Gene\u2019s journey, Achieve\u2019s revolutionary technique, the Parkinson\u2019s panorama, and the way forward for AI in biotech.<\/p>\n<p>\u00b7\u00a0 01:28 Meet Gene Mack\u00a0<\/p>\n<p>\u00b7\u00a0 11:15 GAIN&#8217;s mission: illness modification over symptom reduction\u00a0<\/p>\n<p>\u00b7\u00a0 17:07 Why current Parkinson&#8217;s therapies fall brief\u00a0<\/p>\n<p>\u00b7\u00a0 22:39 Origins and evolution of the Magellan platform\u00a0<\/p>\n<p>\u00b7\u00a0 26:16 How AI modifications drug discovery past simply velocity\u00a0<\/p>\n<p>\u00b7\u00a0 28:13 Part 1b examine design and open-label extension outcomes\u00a0<\/p>\n<p>\u00b7\u00a0 32:09 Partnership technique and path to Part 2\u00a0<\/p>\n<p>\u00b7\u00a0 35:29 Recommendation for leaders in neurodegeneration\u00a0<\/p>\n<p>Involved in being a sponsor of an episode of our podcast? Uncover how one can become involved right here!\u00a0<\/p>\n<p>Keep up to date by subscribing to our publication<\/p>\n<p>To dive deeper into the subject:\u00a0<\/p>\n<\/p><\/div>\n<div id=\"chapters\" role=\"tabpanel\" aria-labelledby=\"transcript-tab\" tabindex=\"0\" dir=\"auto\" data-tabs-target=\"panel\" data-tabs-panel=\"chapters\">\n<div class=\"flex items-center gap-4 pb-3\">\n<p>      11:15<\/p>\n<p>\n    GAIN&#8217;s mission: illness modification over symptom reduction\n  <\/p>\n<\/div>\n<div class=\"flex items-center gap-4 pb-3\">\n<p>      17:07<\/p>\n<p>\n    Why current Parkinson&#8217;s therapies fall brief\n  <\/p>\n<\/div>\n<div class=\"flex items-center gap-4 pb-3\">\n<p>      22:39<\/p>\n<p>\n    Origins and evolution of the Magellan platform\n  <\/p>\n<\/div>\n<div class=\"flex items-center gap-4 pb-3\">\n<p>      26:16<\/p>\n<p>\n    How AI modifications drug discovery past simply velocity\n  <\/p>\n<\/div>\n<div class=\"flex items-center gap-4 pb-3\">\n<p>      28:13<\/p>\n<p>\n    Part 1b examine design and open-label extension outcomes\n  <\/p>\n<\/div>\n<div class=\"flex items-center gap-4 pb-3\">\n<p>      32:09<\/p>\n<p>\n    Partnership technique and path to Part 2\n  <\/p>\n<\/div>\n<div class=\"flex items-center gap-4 pb-3\">\n<p>      35:29<\/p>\n<p>\n    Recommendation for leaders in neurodegeneration\n  <\/p>\n<\/div><\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.labiotech.eu\/podcast\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>At the moment we welcome Gene Mack, President and CEO of Achieve Therapeutics.\u00a0 With over 25 years of expertise spanning biochemistry, Wall Road evaluation, and biotech management, Gene brings deep experience in capital markets, technique, and drug growth. He joined Achieve in 2024 and stepped into the CEO function in early 2025. Achieve Therapeutics is [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3226,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.buzzsprout.com\/rails\/active_storage\/representations\/redirect\/eyJfcmFpbHMiOnsiZGF0YSI6NTM2NjMzNzksInB1ciI6ImJsb2JfaWQifX0=--086debc95d277c62654d62594ec033625acb22fb\/eyJfcmFpbHMiOnsiZGF0YSI6eyJmb3JtYXQiOiJqcGciLCJyZXNpemVfdG9fZmlsbCI6WzI1MCwyNTAseyJjcm9wIjoiY2VudHJlIn1dLCJzYXZlciI6eyJxdWFsaXR5Ijo2MH0sImNvbG91cnNwYWNlIjoic3JnYiJ9LCJwdXIiOiJ2YXJpYXRpb24ifX0=--21f3793904e6ce1806a5a794a691217fceef82c7\/podcast%20v3.jpg","fifu_image_alt":"","jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_override_bookmark_settings":[],"jnews_social_meta":[],"jnews_override_counter":[],"footnotes":""},"categories":[10],"tags":[3646,3645,3644,3647,2542,851],"class_list":["post-3224","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","tag-diseasemodifying","tag-firstinclass","tag-gain","tag-parkinsons","tag-therapeutics","tag-therapy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Achieve Therapeutics: a first-in-class, disease-modifying remedy for Parkinson&#039;s - Future News 24<\/title>\n<meta name=\"description\" content=\"Today we welcome Gene Mack, President and CEO of Gain Therapeutics.&amp;nbsp;With over 25 years of experience spanning biochemistry, Wall Street analysis, and biotech leadership, Gene brings deep expertise in capital markets, strategy, and drug development. He joined Gain in 2024 and stepped into the...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Achieve Therapeutics: a first-in-class, disease-modifying remedy for Parkinson&#039;s - Future News 24\" \/>\n<meta property=\"og:description\" content=\"Today we welcome Gene Mack, President and CEO of Gain Therapeutics.&amp;nbsp;With over 25 years of experience spanning biochemistry, Wall Street analysis, and biotech leadership, Gene brings deep expertise in capital markets, strategy, and drug development. He joined Gain in 2024 and stepped into the...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/\" \/>\n<meta property=\"og:site_name\" content=\"Future News 24\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-31T08:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-03T10:59:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.buzzsprout.com\/rails\/active_storage\/representations\/redirect\/eyJfcmFpbHMiOnsiZGF0YSI6NTM2NjMzNzksInB1ciI6ImJsb2JfaWQifX0=--086debc95d277c62654d62594ec033625acb22fb\/eyJfcmFpbHMiOnsiZGF0YSI6eyJmb3JtYXQiOiJqcGciLCJyZXNpemVfdG9fZmlsbCI6WzI1MCwyNTAseyJjcm9wIjoiY2VudHJlIn1dLCJzYXZlciI6eyJxdWFsaXR5Ijo2MH0sImNvbG91cnNwYWNlIjoic3JnYiJ9LCJwdXIiOiJ2YXJpYXRpb24ifX0=--21f3793904e6ce1806a5a794a691217fceef82c7\/podcast%20v3.jpg\" \/>\n<meta name=\"author\" content=\"Future News 24\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.buzzsprout.com\/rails\/active_storage\/representations\/redirect\/eyJfcmFpbHMiOnsiZGF0YSI6NTM2NjMzNzksInB1ciI6ImJsb2JfaWQifX0=--086debc95d277c62654d62594ec033625acb22fb\/eyJfcmFpbHMiOnsiZGF0YSI6eyJmb3JtYXQiOiJqcGciLCJyZXNpemVfdG9fZmlsbCI6WzI1MCwyNTAseyJjcm9wIjoiY2VudHJlIn1dLCJzYXZlciI6eyJxdWFsaXR5Ijo2MH0sImNvbG91cnNwYWNlIjoic3JnYiJ9LCJwdXIiOiJ2YXJpYXRpb24ifX0=--21f3793904e6ce1806a5a794a691217fceef82c7\/podcast%20v3.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Future News 24\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\\\/\"},\"author\":{\"name\":\"Future News 24\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\"},\"headline\":\"Achieve Therapeutics: a first-in-class, disease-modifying remedy for Parkinson&#8217;s\",\"datePublished\":\"2026-07-31T08:00:00+00:00\",\"dateModified\":\"2026-08-03T10:59:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\\\/\"},\"wordCount\":284,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.buzzsprout.com\\\/rails\\\/active_storage\\\/representations\\\/redirect\\\/eyJfcmFpbHMiOnsiZGF0YSI6NTM2NjMzNzksInB1ciI6ImJsb2JfaWQifX0=--086debc95d277c62654d62594ec033625acb22fb\\\/eyJfcmFpbHMiOnsiZGF0YSI6eyJmb3JtYXQiOiJqcGciLCJyZXNpemVfdG9fZmlsbCI6WzI1MCwyNTAseyJjcm9wIjoiY2VudHJlIn1dLCJzYXZlciI6eyJxdWFsaXR5Ijo2MH0sImNvbG91cnNwYWNlIjoic3JnYiJ9LCJwdXIiOiJ2YXJpYXRpb24ifX0=--21f3793904e6ce1806a5a794a691217fceef82c7\\\/podcast%20v3.jpg\",\"keywords\":[\"diseasemodifying\",\"firstinclass\",\"Gain\",\"Parkinsons\",\"Therapeutics\",\"therapy\"],\"articleSection\":[\"BioTechnology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\\\/\",\"name\":\"Achieve Therapeutics: a first-in-class, disease-modifying remedy for Parkinson's - Future News 24\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.buzzsprout.com\\\/rails\\\/active_storage\\\/representations\\\/redirect\\\/eyJfcmFpbHMiOnsiZGF0YSI6NTM2NjMzNzksInB1ciI6ImJsb2JfaWQifX0=--086debc95d277c62654d62594ec033625acb22fb\\\/eyJfcmFpbHMiOnsiZGF0YSI6eyJmb3JtYXQiOiJqcGciLCJyZXNpemVfdG9fZmlsbCI6WzI1MCwyNTAseyJjcm9wIjoiY2VudHJlIn1dLCJzYXZlciI6eyJxdWFsaXR5Ijo2MH0sImNvbG91cnNwYWNlIjoic3JnYiJ9LCJwdXIiOiJ2YXJpYXRpb24ifX0=--21f3793904e6ce1806a5a794a691217fceef82c7\\\/podcast%20v3.jpg\",\"datePublished\":\"2026-07-31T08:00:00+00:00\",\"dateModified\":\"2026-08-03T10:59:04+00:00\",\"description\":\"Today we welcome Gene Mack, President and CEO of Gain Therapeutics.&amp;nbsp;With over 25 years of experience spanning biochemistry, Wall Street analysis, and biotech leadership, Gene brings deep expertise in capital markets, strategy, and drug development. He joined Gain in 2024 and stepped into the...\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.buzzsprout.com\\\/rails\\\/active_storage\\\/representations\\\/redirect\\\/eyJfcmFpbHMiOnsiZGF0YSI6NTM2NjMzNzksInB1ciI6ImJsb2JfaWQifX0=--086debc95d277c62654d62594ec033625acb22fb\\\/eyJfcmFpbHMiOnsiZGF0YSI6eyJmb3JtYXQiOiJqcGciLCJyZXNpemVfdG9fZmlsbCI6WzI1MCwyNTAseyJjcm9wIjoiY2VudHJlIn1dLCJzYXZlciI6eyJxdWFsaXR5Ijo2MH0sImNvbG91cnNwYWNlIjoic3JnYiJ9LCJwdXIiOiJ2YXJpYXRpb24ifX0=--21f3793904e6ce1806a5a794a691217fceef82c7\\\/podcast%20v3.jpg\",\"contentUrl\":\"https:\\\/\\\/www.buzzsprout.com\\\/rails\\\/active_storage\\\/representations\\\/redirect\\\/eyJfcmFpbHMiOnsiZGF0YSI6NTM2NjMzNzksInB1ciI6ImJsb2JfaWQifX0=--086debc95d277c62654d62594ec033625acb22fb\\\/eyJfcmFpbHMiOnsiZGF0YSI6eyJmb3JtYXQiOiJqcGciLCJyZXNpemVfdG9fZmlsbCI6WzI1MCwyNTAseyJjcm9wIjoiY2VudHJlIn1dLCJzYXZlciI6eyJxdWFsaXR5Ijo2MH0sImNvbG91cnNwYWNlIjoic3JnYiJ9LCJwdXIiOiJ2YXJpYXRpb24ifX0=--21f3793904e6ce1806a5a794a691217fceef82c7\\\/podcast%20v3.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/futurenews24.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Achieve Therapeutics: a first-in-class, disease-modifying remedy for Parkinson&#8217;s\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"name\":\"Future News 24\",\"description\":\"The Smart Hub for AI and Next-Gen Innovation\",\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/futurenews24.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\",\"name\":\"Future News 24\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"contentUrl\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"width\":250,\"height\":250,\"caption\":\"Future News 24\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\",\"name\":\"Future News 24\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"caption\":\"Future News 24\"},\"sameAs\":[\"https:\\\/\\\/futurenews24.com\"],\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/author\\\/mridulpahuja20\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Achieve Therapeutics: a first-in-class, disease-modifying remedy for Parkinson's - Future News 24","description":"Today we welcome Gene Mack, President and CEO of Gain Therapeutics.&amp;nbsp;With over 25 years of experience spanning biochemistry, Wall Street analysis, and biotech leadership, Gene brings deep expertise in capital markets, strategy, and drug development. He joined Gain in 2024 and stepped into the...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/","og_locale":"en_US","og_type":"article","og_title":"Achieve Therapeutics: a first-in-class, disease-modifying remedy for Parkinson's - Future News 24","og_description":"Today we welcome Gene Mack, President and CEO of Gain Therapeutics.&amp;nbsp;With over 25 years of experience spanning biochemistry, Wall Street analysis, and biotech leadership, Gene brings deep expertise in capital markets, strategy, and drug development. He joined Gain in 2024 and stepped into the...","og_url":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/","og_site_name":"Future News 24","article_published_time":"2026-07-31T08:00:00+00:00","article_modified_time":"2026-08-03T10:59:04+00:00","og_image":[{"url":"https:\/\/www.buzzsprout.com\/rails\/active_storage\/representations\/redirect\/eyJfcmFpbHMiOnsiZGF0YSI6NTM2NjMzNzksInB1ciI6ImJsb2JfaWQifX0=--086debc95d277c62654d62594ec033625acb22fb\/eyJfcmFpbHMiOnsiZGF0YSI6eyJmb3JtYXQiOiJqcGciLCJyZXNpemVfdG9fZmlsbCI6WzI1MCwyNTAseyJjcm9wIjoiY2VudHJlIn1dLCJzYXZlciI6eyJxdWFsaXR5Ijo2MH0sImNvbG91cnNwYWNlIjoic3JnYiJ9LCJwdXIiOiJ2YXJpYXRpb24ifX0=--21f3793904e6ce1806a5a794a691217fceef82c7\/podcast%20v3.jpg","type":"","width":"","height":""}],"author":"Future News 24","twitter_card":"summary_large_image","twitter_image":"https:\/\/www.buzzsprout.com\/rails\/active_storage\/representations\/redirect\/eyJfcmFpbHMiOnsiZGF0YSI6NTM2NjMzNzksInB1ciI6ImJsb2JfaWQifX0=--086debc95d277c62654d62594ec033625acb22fb\/eyJfcmFpbHMiOnsiZGF0YSI6eyJmb3JtYXQiOiJqcGciLCJyZXNpemVfdG9fZmlsbCI6WzI1MCwyNTAseyJjcm9wIjoiY2VudHJlIn1dLCJzYXZlciI6eyJxdWFsaXR5Ijo2MH0sImNvbG91cnNwYWNlIjoic3JnYiJ9LCJwdXIiOiJ2YXJpYXRpb24ifX0=--21f3793904e6ce1806a5a794a691217fceef82c7\/podcast%20v3.jpg","twitter_misc":{"Written by":"Future News 24","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/#article","isPartOf":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/"},"author":{"name":"Future News 24","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83"},"headline":"Achieve Therapeutics: a first-in-class, disease-modifying remedy for Parkinson&#8217;s","datePublished":"2026-07-31T08:00:00+00:00","dateModified":"2026-08-03T10:59:04+00:00","mainEntityOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/"},"wordCount":284,"commentCount":0,"publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/#primaryimage"},"thumbnailUrl":"https:\/\/www.buzzsprout.com\/rails\/active_storage\/representations\/redirect\/eyJfcmFpbHMiOnsiZGF0YSI6NTM2NjMzNzksInB1ciI6ImJsb2JfaWQifX0=--086debc95d277c62654d62594ec033625acb22fb\/eyJfcmFpbHMiOnsiZGF0YSI6eyJmb3JtYXQiOiJqcGciLCJyZXNpemVfdG9fZmlsbCI6WzI1MCwyNTAseyJjcm9wIjoiY2VudHJlIn1dLCJzYXZlciI6eyJxdWFsaXR5Ijo2MH0sImNvbG91cnNwYWNlIjoic3JnYiJ9LCJwdXIiOiJ2YXJpYXRpb24ifX0=--21f3793904e6ce1806a5a794a691217fceef82c7\/podcast%20v3.jpg","keywords":["diseasemodifying","firstinclass","Gain","Parkinsons","Therapeutics","therapy"],"articleSection":["BioTechnology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/","url":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/","name":"Achieve Therapeutics: a first-in-class, disease-modifying remedy for Parkinson's - Future News 24","isPartOf":{"@id":"https:\/\/futurenews24.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/#primaryimage"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/#primaryimage"},"thumbnailUrl":"https:\/\/www.buzzsprout.com\/rails\/active_storage\/representations\/redirect\/eyJfcmFpbHMiOnsiZGF0YSI6NTM2NjMzNzksInB1ciI6ImJsb2JfaWQifX0=--086debc95d277c62654d62594ec033625acb22fb\/eyJfcmFpbHMiOnsiZGF0YSI6eyJmb3JtYXQiOiJqcGciLCJyZXNpemVfdG9fZmlsbCI6WzI1MCwyNTAseyJjcm9wIjoiY2VudHJlIn1dLCJzYXZlciI6eyJxdWFsaXR5Ijo2MH0sImNvbG91cnNwYWNlIjoic3JnYiJ9LCJwdXIiOiJ2YXJpYXRpb24ifX0=--21f3793904e6ce1806a5a794a691217fceef82c7\/podcast%20v3.jpg","datePublished":"2026-07-31T08:00:00+00:00","dateModified":"2026-08-03T10:59:04+00:00","description":"Today we welcome Gene Mack, President and CEO of Gain Therapeutics.&amp;nbsp;With over 25 years of experience spanning biochemistry, Wall Street analysis, and biotech leadership, Gene brings deep expertise in capital markets, strategy, and drug development. He joined Gain in 2024 and stepped into the...","breadcrumb":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/#primaryimage","url":"https:\/\/www.buzzsprout.com\/rails\/active_storage\/representations\/redirect\/eyJfcmFpbHMiOnsiZGF0YSI6NTM2NjMzNzksInB1ciI6ImJsb2JfaWQifX0=--086debc95d277c62654d62594ec033625acb22fb\/eyJfcmFpbHMiOnsiZGF0YSI6eyJmb3JtYXQiOiJqcGciLCJyZXNpemVfdG9fZmlsbCI6WzI1MCwyNTAseyJjcm9wIjoiY2VudHJlIn1dLCJzYXZlciI6eyJxdWFsaXR5Ijo2MH0sImNvbG91cnNwYWNlIjoic3JnYiJ9LCJwdXIiOiJ2YXJpYXRpb24ifX0=--21f3793904e6ce1806a5a794a691217fceef82c7\/podcast%20v3.jpg","contentUrl":"https:\/\/www.buzzsprout.com\/rails\/active_storage\/representations\/redirect\/eyJfcmFpbHMiOnsiZGF0YSI6NTM2NjMzNzksInB1ciI6ImJsb2JfaWQifX0=--086debc95d277c62654d62594ec033625acb22fb\/eyJfcmFpbHMiOnsiZGF0YSI6eyJmb3JtYXQiOiJqcGciLCJyZXNpemVfdG9fZmlsbCI6WzI1MCwyNTAseyJjcm9wIjoiY2VudHJlIn1dLCJzYXZlciI6eyJxdWFsaXR5Ijo2MH0sImNvbG91cnNwYWNlIjoic3JnYiJ9LCJwdXIiOiJ2YXJpYXRpb24ifX0=--21f3793904e6ce1806a5a794a691217fceef82c7\/podcast%20v3.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/futurenews24.com\/"},{"@type":"ListItem","position":2,"name":"Achieve Therapeutics: a first-in-class, disease-modifying remedy for Parkinson&#8217;s"}]},{"@type":"WebSite","@id":"https:\/\/futurenews24.com\/#website","url":"https:\/\/futurenews24.com\/","name":"Future News 24","description":"The Smart Hub for AI and Next-Gen Innovation","publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/futurenews24.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/futurenews24.com\/#organization","name":"Future News 24","url":"https:\/\/futurenews24.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/","url":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","contentUrl":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","width":250,"height":250,"caption":"Future News 24"},"image":{"@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83","name":"Future News 24","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","caption":"Future News 24"},"sameAs":["https:\/\/futurenews24.com"],"url":"https:\/\/futurenews24.com\/index.php\/author\/mridulpahuja20\/"}]}},"_links":{"self":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/3224","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/comments?post=3224"}],"version-history":[{"count":1,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/3224\/revisions"}],"predecessor-version":[{"id":3225,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/3224\/revisions\/3225"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media\/3226"}],"wp:attachment":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media?parent=3224"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/categories?post=3224"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/tags?post=3224"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}